Kamada Ltd.

KMDA ·Healthcare, Drug Manufacturers - General, Israel
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015
Revenue $102.8M $77.5M $69.9M
Cost of Revenue $70.7M $56.1M $54.5M
Gross Profit $32.1M $21.4M $15.4M
Gross Margin 31.2% 27.6% 22.0%
Operating Expenses
Research & Development — — —
SG&A Expense — — —
Operating Income $7.4M $-5.5M $-11.4M
Operating Margin 7.2% -7.1% -16.3%
Interest Expense — — —
Pretax Income $7.2M $-5.0M $-11.3M
Income Tax Expense $269.0K $1.7M —
Net Income $6.9M $-6.7M $-11.3M
Net Margin 6.7% -8.7% -16.1%
EPS (Basic) $0.18 $-0.18 $-0.31
EPS (Diluted) $0.18 $-0.18 $-0.31
Shares Outstanding (Basic) 40.3M — —
Shares Outstanding (Diluted) 40.3M — —
Dividends Per Share — — —
← Newer Page 2 of 2 Older →